Dr. Reddy’s Laboratories has introduced Toripalimab in India, marking it as the first and only immuno-oncology therapy approved for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)
The drug is previously approved by regulatory bodies such as the USFDA, EMA, MHRA, and others, providing treatment options for adult patients facing this challenging cancer type
Toripalimab, in combination with standard chemotherapy, has demonstrated a 48% reduction in disease progression or mortality. India’s launch coincides with its availability in the United States, making India the third country globally to access this innovative treatment after China and the U.S.
In 2023, Dr. Reddy’s entered into an agreement with Shanghai Junshi Biosciences, granting exclusive rights to develop and market toripalimab across 21 countries, including India, South Africa, and regions in Latin America. The agreement also allows for expansion into Australia, New Zealand, and additional territories. In India, toripalimab will be marketed under the brand name Zytorvi.
Changing the Standard of Care
Previously, the primary treatment for RM-NPC in India involved chemotherapy with gemcitabine and cisplatin. Toripalimab is now approved as a first-line treatment in combination with these chemotherapy agents, significantly lowering the risk of disease progression. It is also authorized as a standalone therapy for patients with advanced or recurrent NPC who have not responded to platinum-based chemotherapy.
Nasopharyngeal carcinoma originates from the epithelial cells in the nasopharynx. According to GLOBOCAN 2022, over 120,000 new NPC cases were reported globally, with India accounting for 6,519 of those cases. The highest incidence rates in India are found in northeastern regions, particularly in Kohima, Nagaland.
Toripalimab - Mechanism of Action
Toripalimab is a monoclonal antibody designed to block PD-1 receptors from interacting with their ligands, PD-L1 and PD-L2. By inhibiting these interactions, the drug enhances the immune system’s ability to recognize and destroy cancer cells. This mechanism helps prevent tumour growth and supports better outcomes for patients with RM-NPC.
The launch of Toripalimab represents a significant advancement in cancer care for Indian patients, offering a promising new option to combat nasopharyngeal carcinoma.
Comments